Evidence map›Paper›PMID 36860313›Full record

ArticleFrontiers in oncology2023

Identification of

Reihane Kazerani, Pouya Salehipour, Mohammadreza Shah Mohammadi, Elnaz Amanzadeh Jajin, Mohammad Hossein Modarressi

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Reihane KazeraniDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Pouya SalehipourDepartment of Medical Genetics, School of Medicine, Tehran University of Medical Science, Tehran, Iran.
Mohammadreza Shah MohammadiFunctional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Science, Tehran, Iran.
Elnaz Amanzadeh JajinFunctional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Science, Tehran, Iran.
Mohammad Hossein ModarressiDepartment of Medical Genetics, School of Medicine, Tehran University of Medical Science, Tehran, Iran.
Shahid Beheshti University of Medical Sciences · IRUniversity of Tehran · IRIslamic Azad University, Science and Research Branch · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Brain tumors (BTs) are perceived as one of the most common malignancies among children. The specific regulation of each gene can play a critical role in cancer progression. The present study aimed to determine the transcripts of the Material and methods: Public data on brain tumor microarray datasets in GEO were analyzed with R software to evaluate the expression levels of Results: In silico results show that the differential expression levels of Conclusion: The decreased expression levels of transcripts with longer 5'UTR in BT samples than in testicular or low-grade brain tumor samples may decrease their translation efficiency. Therefore, decreased amounts of TSGA10 and GGNBP2 as potential tumor suppressor proteins, especially in high-grade brain tumors, may cause cancer development by angiogenesis and metastasis.

Indexed as

5’ untranslated regionalternative splicing (AS)brain tumorscancer testis antigens (CTA)gametogenetin binding protein 2 (GGNBP2)testis specific gene antigen 10 (TSGA10)

Identifiers

PMID36860313
PMCPMC9968883
OpenAlexW4320495717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.